CoChat
Sign Up
Cited by 143Ovarian function and disordersLipoproteins and Cardiovascular HealthAcne and Rosacea Treatments and Effects

Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial

Banaszewska, Beata, Pawelczyk, Leszek, Spaczynski, Robert Z., Dziura, James, Duleba, Antoni J.·2007·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2006-1988
Open this paper in CoChat — free account

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and cardiovascular risks including dyslipidemia and systemic inflammation. In vitro, statins decrease proliferation and steroidogenesis of ovarian theca-interstitial cells. OBJECTIVE: The study objective was to compare effects of two treatments of PCOS: simvastatin plus oral contraceptive pill (OCP) vs. OCP alone. DESIGN: In a prospective, crossover trial, 48 women with PCOS were randomized to either simvastatin plus OCP for 12 wk followed by OCP alone for an additional 12 wk, or to OCP alone for 12 wk and, subsequently, simvastatin plus OCP for an additional 12 wk. Evaluations were performed at baseline, after 12 wk (crossover), and after 24 wk. Data were analyzed using a random effects model. SETTING: The study was conducted in an academic medical center. PRIMARY OUTCOME: Serum total testosterone was the primary outcome measure. RESULTS: Total testosterone decreased by 38% after Statin + OCP, whereas OCP alone led to a 26% decrease; the statin-attributable effect was significant (P < 0.004). Free testosterone declined by 58% after Statin + OCP, significantly more than the 35% decline after OCP alone (P = 0.006). Hirsutism decreased by 8.1% after Statin + OCP, a greater effect than the 4.7% decrease after OCP alone (P = 0.02). Statin decreased LH, but not FSH or prolactin. Statin + OCP decreased total and low-density lipoprotein cholesterol by 7.5% and 20%, respectively. OCP alone led to a 5% increase of total cholesterol without effect on low-density lipoprotein cholesterol. Statin prevented OCP induced increase of triglycerides. C-reactive protein decreased by 45% after Statin + OCP, a significantly different effect (P = 0.006) than a 6% increase after OCP alone. Soluble vascular cell adhesion molecule 1 decreased by 18% after Statin + OCP, a greater decline than the 10% decrease after OCP alone (P = 0.01). CONCLUSIONS: Simvastatin improved endocrine/clinical aspects of PCOS and had beneficial effects on lipid profile and markers of systemic inflammation.

Integrity signals

Registry

Crossref · 10.1210/jc.2006-1988

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Banaszewska, B., Pawelczyk, L., Spaczynski, R. Z., Dziura, J., & Duleba, A. J.
Affiliations
  • Poznan University of Medical Sciences (PL)
  • Department of Gynecology/Obstetrics (B.B., L.P., R.Z.S.), Poznan University of Medical Sciences, 60-535 Poznan, Poland
  • Yale University (US)
  • Department of Obstetrics and Gynecology (A.J.D.), Yale University School of Medicine, New Haven, Connecticut 06520
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2006-11-14
Volume
92
Issue
2
Pages
456-461
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2006-1988
OpenAlex
W1995813378
Cited by
143
References
51
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 12 · 2012: 8
FWCI
11.99
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hd040207-04)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD40207)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
Keywords
polycystic ovary syndrome, simvastatin, oral contraceptives, hyperandrogenism, testosterone, free testosterone, hirsutism, luteinizing hormone, cholesterol, triglycerides, C-reactive protein, soluble vascular cell adhesion molecule-1, inflammation, cardiovascular risk, statins, theca-interstitial cells, ovarian steroidogenesis, dyslipidemia
MeSH terms
Adult, Hypolipidemic Agents, Contraceptives, Oral, Combined, Drug Therapy, Combination, Estrogens, Ethinyl Estradiol, Female, Humans, Pituitary Hormones, Polycystic Ovary Syndrome, Prospective Studies, Testosterone, Treatment Outcome, Desogestrel, Cross-Over Studies, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review